FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.40 USD
+0.01 (1.32%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $0.41 +0.01 (2.50%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.40 USD
+0.01 (1.32%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $0.41 +0.01 (2.50%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Zacks News
Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?
by Zacks Equity Research
Kite Pharma, Inc. (KITE) is expected to report first-quarter 2017 results on May 8 before the market opens.
Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month.
Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes.
What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.
Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings?
by Zacks Equity Research
Intrexon Corporation (XON) is expected to report first-quarter 2017 results on May 9.
GW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect?
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) is expected to report second-quarter fiscal 2017 results on May 4.
What's in the Cards for ACADIA (ACAD) this Earnings Season?
by Zacks Equity Research
ACADIA Pharmaceuticals Inc. (ACAD) is expected to report first-quarter 2017 results on May 4.
Radius Health (RDUS) Q1 Earnings: What's in Store?
by Zacks Equity Research
Radius Health, Inc. (RDUS) is scheduled to report first-quarter 2017 financial results on May 3.
What's in Store for Zoetis (ZTS) Stock This Earnings Season?
by Zacks Equity Research
Zoetis Inc. (ZTS) is scheduled to report first-quarter 2017 results on May 4.
What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?
by Zacks Equity Research
Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3.
Is Intercept (ICPT) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Is Intercept (ICPT) Poised for a Beat this Earnings Season?
What to Expect from Keryx (KERX) Stock This Earnings Season?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2017 results on May 4.
What's in the Cards for Merrimack (MACK) in Q1 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations
What to Expect from Prothena (PRTA) This Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.
What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2.
Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%
by Zacks Equity Research
Aurinia Pharmaceuticals Inc. (AUPH) moved big last session, as its shares jumped almost 6% on the day.
FibroGen (FGEN) Shares March Higher, Can It Continue?
by Zacks Equity Research
FibroGen, Inc. (FGEN) has been on the move lately as the stock has risen by 29.3% in the past four weeks, and it is currently trading well above its 20-Day SMA